Sun Pharma Secures South African Approval for Generic Semaglutide The South African Health Products Regulatory Authority (SAHPRA) has granted Sun Pharmaceutical Industries approval to market a generic version of the …
Tag:
Semaglutide
-
-
The New Weight-Loss Pill vs. the Injection: A Doctor’s Honest Take on Oral Wegovy and Wegovy The new weight-loss pill Rybelsus and the injection Wegovy offer different approaches to managing …
-
The rise of GLP-1 receptor agonists, such as semaglutide, has moved beyond clinical settings and into the wedding industry, with some individuals increasingly seeking these medications for weight management ahead …
-
Understanding Weight Loss Variability with GLP-1 Receptor Agonists Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, produce significant weight loss in many patients, yet clinical outcomes vary widely …
-
GLP-1 receptor agonists are a class of injectable medications primarily used to manage blood sugar levels in adults with Type 2 diabetes and to support weight loss in individuals with …
-
Understanding Ozempic: Clinical Indications and Medical Context As a physician, I frequently discuss the role of semaglutide—the active ingredient in Ozempic—with patients seeking to manage complex health conditions. While recent …
-
Suboptimal Adherence to Treat-to-Target Rheumatic Strategies: A Critical Challenge in Rheumatoid Arthritis Care Recent real-world studies highlight a significant gap between recommended rheumatic disease management protocols and their implementation in …
-
Retatrutide and the Future of Obesity Treatment: Insights from the TRIUMPH-1 Study The landscape of obesity medicine is evolving rapidly. Eli Lilly’s investigational drug, retatrutide, has recently garnered significant attention …
-
Health
How GLP-1s are more than just weight-loss wonders – but not without risk – South China Morning Post
Understanding GLP-1 Agonists: A Comprehensive Guide to Modern Metabolic Treatment In recent years, the medical landscape has been transformed by a class of medications known as glucagon-like peptide-1 (GLP-1) receptor …
-
Zydus Lifesciences Reports Growth in Q4 FY26 Financial Results Zydus Lifesciences has reported its financial performance for the fourth quarter (Q4) of the 2025-26 financial year (FY26), highlighting a period …
Newer Posts